Redeye leaves a short comment following OncoZenge’s announcement of having received the third tranche from its investment agreement with Yangtian. We are encouraged to see that the company has resolved the recent short-term financing uncertainty, restoring stability and maintaining momentum ahead of the upcoming phase III CTA milestone.
LÄS MER
